Market Closed -
Japan Exchange
02:00:00 2024-04-26 am EDT
5-day change
1st Jan Change
1,502
JPY
+1.49%
+5.55%
-11.54%
Shin Nippon Biomedical Laboratories, Ltd. Revises Year End Dividend Guidance for the Year Ending March 31, 2023
January 31, 2023 at 01:30 am EST
Shin Nippon Biomedical Laboratories, Ltd. revised year end dividend guidance of JPY 30.00 per share for the year ending March 31, 2023 compared to JPY 30.00 per share a year ago.
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024
Feb. 01
CI
Shin Nippon's STS101 Faces Regulatory Hurdle, FDA Requests Refinement for Approval
Jan. 18
MT
Shin Nippon Biomedical Laboratories, Ltd. Announces Interim Dividend for the Year Ending March 31, 2024, Payable on November 30, 2023; Provides Dividend Guidance for the Year Ending March 31, 2024
Nov. 07
CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for Second Quarter and Full Year Ending March 31, 2024
23-08-01
CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024
23-08-01
CI
Satsuma Pharmaceuticals and Shin Nippon Biomedical Laboratories, Ltd. Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to Be Presented at the American Headache Society's 65th Annual Scientific Meeting
23-06-15
CI
Shin Nippon Biomedical Laboratories, Ltd. completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers.
23-06-07
CI
Jefferies Upgrades Shin Nippon Biomedical Laboratories to Buy From Hold, Adjusts Price Target to 2,800 Yen From 2,300 Yen
23-05-29
MT
Shin Nippon Biomedical Laboratories, Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023
23-05-08
CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for Second Quarter and Full Year Ending March 31, 2024
23-05-08
CI
Shin Nippon Biomedical Laboratories, Ltd. Announces Year End Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023
23-05-08
CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024
23-05-08
CI
Jefferies Downgrades Shin Nippon Biomedical Laboratories to Hold From Buy, Adjusts Price Target to 2,300 Yen From 3,800 Yen
23-04-18
MT
Shin Nippon Biomedical to Make $30 Million Offer for US-based Satsuma Pharmaceuticals
23-04-18
MT
Sector Update: Health Care Stocks Higher Premarket Monday
23-04-17
MT
Bank Earnings in Focus as US Equity Futures Tread Water
23-04-17
MT
Top Premarket Gainers
23-04-17
MT
Satsuma Pharmaceuticals to be Acquired by Shin Nippon Biomedical
23-04-17
MT
Shin Nippon Biomedical Laboratories, Ltd. entered into an agreement to acquire the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers for $27.6 million.
23-04-16
CI
Shin Nippon Biomedical Laboratories, Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023
23-01-31
CI
Shin Nippon Biomedical Laboratories, Ltd. Revises Year End Dividend Guidance for the Year Ending March 31, 2023
23-01-31
CI
Shin Nippon Biomedical Laboratories, Ltd. Announced Dividend for the Second Quarter of Fiscal Year Ending March 31, 2023, Commence Payments from November 30, 2022
22-10-31
CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023
22-10-31
CI
Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023
22-10-31
CI
Shin Nippon Biomedical Laboratories, Ltd. Announces Dividend on Retained Earnings, Effective November 30, 2022
22-10-31
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. is a Japan-based company mainly engaged in the provision of clinical trials and drug development services for pharmaceutical companies. The Company has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.
More about the company
Last Close Price
1,502
JPY
Average target price
3,150
JPY
Spread / Average Target
+109.72%
Consensus
1st Jan change
Capi.
-11.54% 397M +1.51% 42.75B +49.22% 41.61B +8.57% 41.34B -12.36% 26.59B +8.92% 25.49B -25.13% 18.12B +29.17% 12.24B -3.12% 11.76B +6.35% 11B
Other Biotechnology & Medical Research
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. 
